

A pharmaceutical breakthrough just opened doors for patients with a heart condition that's never had an approved treatment.

Cytokinetics' drug Myqorzo succeeded in treating non-obstructive hypertrophic cardiomyopathy, doubling the number of people who could benefit from this therapy.

Want to know more?